Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

FAM98A Inhibitors

FAM98A inhibitors, as identified in the context of its specific roles in protein arginine methylation, skeletal homeostasis, and osteoclast function, encompass a range of compounds that indirectly influence these processes. Notably, inhibitors like AMI-1, sodium salt target the activity of protein arginine methyltransferases (PRMTs), potentially impacting the FAM98A-mediated methylation process. Such inhibitors are crucial for understanding the regulatory mechanisms of protein methylation, a post-translational modification essential for various cellular functions. The role of FAM98A in osteoclast function and skeletal homeostasis brings bisphosphonates such as Zoledronic acid, anhydrous, Alendronate Sodium Salt Trihydrate, Risedronic acid, and Ibandronate Sodium Monohydrate into focus. These compounds inhibit osteoclast-mediated bone resorption, thereby potentially affecting the involvement of FAM98A in bone metabolism. Similarly, inhibitors like Calcitonin, Salmon, which reduces osteoclast activity, and Denosumab, a RANK Ligand inhibitor affecting osteoclast differentiation, are pertinent for their potential indirect influence on FAM98A's role in bone remodeling. Autophagy inhibitors like Chloroquine, which may affect lysosome function and distribution, are also relevant given FAM98A's role in osteoclasts. The application of these inhibitors provides valuable insights into the physiological and pathological roles of FAM98A. For instance, Cytochalasin D, which disrupts actin filament formation, could indirectly impact FAM98A's involvement in osteoclast morphology and function, highlighting the protein's role in cytoskeletal dynamics. Cathepsin K inhibitors like Odanacatib and cysteine protease inhibitors such as E-64 further elucidate FAM98A's function in lysosomal processes within osteoclasts. The use of Bafilomycin A1, inhibiting vacuolar-type H+-ATPase, underscores the importance of acidic environments in lysosomal function, relevant to FAM98A's role. These inhibitors collectively serve as tools to dissect the complex interactions and functions of FAM98A in cellular processes.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

AMI-1, sodium salt

20324-87-2sc-205928
sc-205928A
5 mg
25 mg
$114.00
$398.00
2
(1)

AMI-1, sodium salt is an inhibitor of protein arginine methyltransferases (PRMTs), potentially impacting FAM98A's role in PRMT1-induced protein arginine methylation.

Zoledronic acid, anhydrous

118072-93-8sc-364663
sc-364663A
25 mg
100 mg
$92.00
$256.00
5
(0)

As a bisphosphonate, Zoledronic acid, anhydrous inhibits bone resorption, potentially influencing FAM98A's involvement in skeletal homeostasis and osteoclast function.

Calcitonin, Salmon

47931-85-1sc-201167
sc-201167A
1 mg
5 mg
$154.00
$625.00
1
(0)

Calcitonin, Salmon reduces osteoclast activity, which may indirectly impact FAM98A's role in skeletal homeostasis and bone remodeling.

Odanacatib

603139-19-1sc-364675
sc-364675A
sc-364675B
5 mg
25 mg
250 mg
$218.00
$993.00
$1982.00
2
(1)

Odanacatib is a Cathepsin K inhibitor, potentially affecting FAM98A's role in osteoclast ruffled border formation and function.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Chloroquine, an autophagy inhibitor, may affect lysosome function and distribution, indirectly impacting FAM98A's role in osteoclasts.

Alendronate acid

66376-36-1sc-337520
5 g
$135.00
2
(0)

Alendronate Sodium Salt Trihydrate, a bisphosphonate, inhibits osteoclast-mediated bone resorption, potentially affecting FAM98A's role in bone metabolism.

Cytochalasin D

22144-77-0sc-201442
sc-201442A
1 mg
5 mg
$165.00
$486.00
64
(4)

Cytochalasin D disrupts actin filament formation, potentially affecting FAM98A's involvement in osteoclast morphology and function.

E-64

66701-25-5sc-201276
sc-201276A
sc-201276B
5 mg
25 mg
250 mg
$281.00
$947.00
$1574.00
14
(0)

E-64 is a cysteine protease inhibitor, which could impact lysosomal function and potentially FAM98A's role in osteoclasts.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

Bafilomycin A1 inhibits vacuolar-type H+-ATPase, potentially affecting lysosomal acidification and FAM98A-related processes in osteoclasts.

Risedronic acid

105462-24-6sc-203239
100 mg
$107.00
2
(1)

Risedronic acid is a bisphosphonate that can influence bone turnover, potentially impacting FAM98A′s function in skeletal homeostasis.